MDNA
NASDAQMedicenna Therapeutics Corp.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Latest news
25 items- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- 13D/GSEC Form SC 13G/A filed by Medicenna Therapeutics Corp. (Amendment)SC 13G/A - Medicenna Therapeutics Corp. (0001807983) (Subject)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- SECSEC Form 25-NSE filed by Medicenna Therapeutics Corp.25-NSE - Medicenna Therapeutics Corp. (0001807983) (Subject)
- NEWSMedicenna To Present 4 Year Follow-Up Phase 2b Bizaxofusp Survival Data In Recurrent Glioblastoma At The Society For Neuro-Oncology 2023 Annual MeetingMedicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by:Dr Steven Brem, M.D., Medical Director, Centre for Precision Surgery, Abramson Cancer Center, Perelman School of Medici
- PRMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingTORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by: Dr Steven Brem, M.D., Medical Director, Centre for Precisio
- SECSEC Form 6-K filed by Medicenna Therapeutics Corp.6-K - Medicenna Therapeutics Corp. (0001807983) (Filer)
- PRMedicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patientMDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage of tumor size following failure with check-point inhibitor therapiesMDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the dose escalation cohortsMedicenna believes that these data reaffirm the differentiated and
- NEWSMedicenna Presents Preclinical Data On MDNA113, Its Targeted Metalloprotease Activated SuperKine At The 38th Annual Meeting Of The Society For Immunotherapy Of CancerCompany's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymesIL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patientsTORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (
- PRMedicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patients TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Com
- NEWSWhy Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving PremarketGainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares jumped 232% to $3.36 in pre-market trading. United Therapeutics Corporation (NASDAQ:UTHR) agreed to acquire Miromatrix Medical for $3.25 per share in cash (an aggregate of approximately $91 million). Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares surged 70.6% to $1.74 in pre-market trading after falling more than 12% on Friday. reAlpha Tech Corp. (NASDAQ:AIRE) shares gained 22% to $28.26 in pre-market trading after dipping around 54% on Friday. My Size, Inc. (NASDAQ:MYSZ) shares climbed 21.4% to $0.8498 in pre-market trading. Coherus BioSciences, Inc. (NASDAQ:CHRS) shares rose 16.2% to $3.07 in pre-market trading. Coherus and Junsh
- NEWSWhy Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day SessionGainers Apollomics, Inc. (NASDAQ:APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. BIO-key International, Inc. (NASDAQ:BKYI) jumped 53.5% to $0.2620 after the company said ALPI Portugal Lda. has deployed AuthControl Sentry company-wide for enhanced data access security through BIO-key. SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 42.5% to $1.1284. SeaStar Medical Holding said it is requesting to withdraw the registration statement because it has elected not to pursue the sale of securities pursuant to the registrant statement at this time due to prevailing market conditions. NerdWallet, Inc. (NASDAQ:NRDS) gained 27.7% to $8.48 following str
- NEWSMedicenna Therapeutics shares are trading lower after the company announced it will be delisted from the Nasdaq and is cutting back its management team.
- NEWSNasdaq Jumps 100 Points; Amazon Posts Upbeat EarningsU.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Friday. Following the market opening Friday, the Dow traded down 0.12% to 32,744.42 while the NASDAQ rose 0.82% to 12,699.50. The S&P 500 also rose, gaining, 0.24% to 4,147.09. Check This Out: Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday Leading and Lagging Sectors Consumer discretionary shares rose by 2.4% on Friday. In trading on Friday, energy shares dipped by 1.7%. Top Headline Amazon.com Inc (NASDAQ:AMZN) reported stronger-than-expected results for its third quarter on Thursday. Amazon said revenue increased 13% year-over-year to $143.
- NEWSMedicenna Announces Nasdaq Delisting And Cutback Of Management Team
- NEWSMedicenna Therapeutics Gets Staff Delisting Determination From the Listing Qualifications Department Nasdaq On Failure To comply With The $1.00 Per Share Minimum Bid Price Requirement
- PRMedicenna Announces Nasdaq Delisting and Cutback of Management TeamTORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") ((NASDAQ, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq"), which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company's failure to comply with the US$1.00 per share minimum bid price requirement. The Company informed Nasdaq that it would not appeal the delisting decision or try to regain compliance by ex
- NEWSReported Earlier, Medicenna Therapeutics Doses First Patient In Phase 2 Monotherapy Dose Expansion Portion Of The ABILITY Study Evaluating MDNA11 In Select Types Of Solid TumorsNew data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024TORONTO and HOUSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (A Beta-only IL-2 ImmunoTherapY) study
MDNA FAQ
5 questionsWhat does Medicenna Therapeutics Corp. do?
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to...Where does MDNA stock trade?
Medicenna Therapeutics Corp. (MDNA) is listed on NASDAQ.What sector and industry is MDNA in?
Medicenna Therapeutics Corp. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to MDNA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MDNA side-by-side with any of them on Quantisnow.How can I track MDNA on Quantisnow?
Quantisnow aggregates Medicenna Therapeutics Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDNA to receive live email and push alerts on every new disclosure.